ProfileGDS5678 / 1426012_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 59% 60% 54% 59% 59% 58% 58% 59% 63% 67% 59% 60% 62% 60% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.5755259
GSM967853U87-EV human glioblastoma xenograft - Control 23.5768860
GSM967854U87-EV human glioblastoma xenograft - Control 33.3262354
GSM967855U87-EV human glioblastoma xenograft - Control 43.5089559
GSM967856U87-EV human glioblastoma xenograft - Control 53.5134359
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6060658
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5646858
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5527359
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7422863
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.0662267
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.5618759
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.557360
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7052562
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5698160